American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update

J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.04.031. Epub 2014 May 5.


Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007 and 2009. The position papers were developed by a special committee appointed by the board and composed of clinicians with extensive experience in caring for these patients and basic science researchers. The knowledge base and experience in addressing MRONJ has expanded, necessitating modifications and refinements to the previous position paper. This special committee met in September 2013 to appraise the current literature and revise the guidelines as indicated to reflect current knowledge in this field. This update contains revisions to diagnosis, staging, and management strategies and highlights current research status. The AAOMS considers it vitally important that this information be disseminated to other relevant health care professionals and organizations.

Publication types

  • Practice Guideline

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Antineoplastic Agents / adverse effects
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / diagnosis
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology*
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / therapy
  • Bone Density Conservation Agents / adverse effects*
  • Bone Remodeling / drug effects
  • Bone Resorption / prevention & control
  • Diagnosis, Differential
  • Humans
  • Jaw Diseases / chemically induced*
  • Jaw Diseases / diagnosis
  • Jaw Diseases / therapy
  • Neoplasms / drug therapy
  • Neovascularization, Physiologic / drug effects
  • Oral Surgical Procedures / adverse effects
  • Osteonecrosis / chemically induced*
  • Osteonecrosis / diagnosis
  • Osteonecrosis / therapy
  • Osteoporosis / drug therapy
  • Patient Care Planning
  • Risk Assessment
  • Risk Factors
  • Terminology as Topic
  • Time Factors


  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Bone Density Conservation Agents